Procter & Gamble Health today announced its financial results for the quarter and fiscal year ending 30th June, 2021. The company has recorded sales of Rs 281 crores in the quarter ending 30th June, up by 40 per cent v/s year ago, according to a company statement.
The statement notified that the company recorded sales of Rs 990.8 crores for the twelve-month fiscal year ending 30th June, 2021. Results for the fiscal are not comparable v/s Rs 1,329 crore sales for the eighteen-months period last year ending 30th June, 2020. The Profit After Tax (PAT) for the year ending 30th June, 2021 is Rs 176.8 crores against Rs 254.08 crores in the previous 18 months fiscal year ending 30th June, 2020.
Speaking on the results, Milind Thatte, Managing Director, Procter & Gamble Health, said, “Given the uncertainty still presented by the pandemic, we continue to work towards protecting the health and safety of our employees and partners, ensuring uninterrupted supplies of our vitamins, minerals, supplements and medicinal products for our patients and consumers, and on supporting communities and relief efforts. As part of the ‘P&G Suraksha India’ COVID-19 relief programme, we contributed to the donation of 10 lakh vaccine doses for five lakh citizens in partnership with state governments and local authorities. We continue to invest in strengthening public health in India through our flagship CSR programme ‘SEHAT.’ Under SEHAT, we recently announced a three-year collaboration with Tata Trusts for ‘YES To POSHAN’, a new initiative which aims to advance the nutritional status of women and children at grassroots.”
The Board of Directors has recommended a final dividend of Rs 130 per equity share, which includes a one-time special dividend of Rs 90 per equity share, for the financial year ending 30th June, 2021, subject to the approval of shareholders of the company at the ensuing 54th Annual General Meeting, mentioned the statement.